
- Applied Clinical Trials-02-01-2011
- Volume 20
- Issue 2
Cardiovascular Drug Trial Discontinued
Merck's cardiovascular drug vorapaxar study was halted.
In mid-January, a combined Data Safety and Monitoring Board (DSMB) halted one of two Phase III trials of Merck's investigational anti-clotting drug vorapaxar because of increased risk of bleeding—specifically intracranial hemorrhage—in subjects with a history of stroke.
The TRACER study was being conducted by Duke Clinical Research Institute. It was fully enrolled in June 2010 and included 13,000 subjects with non-ST-segment-elevation acute coronary syndrome. TRA-2P, or TIMI 50 as the trial was also known, was fully enrolled in November 2009 and included 26,500 subjects who had previously experienced a heart attack. The study was being conducted by Brigham and Women's Hospital.
The DSMB instructed TRACER investigators to discontinue the study drug in subjects and begin close-out activities. For TRA-2P, investigators were told to discontinue the study drug in those who experienced a stroke prior to entering or during the course of the study. They could continue the study drug in those who entered the trial with a history of a previous heart attack or peripheral arterial disease, an estimated 75% of the subjects.
The
Articles in this issue
almost 16 years ago
Applied Clinical Trials Digital Edition - February 2011almost 16 years ago
Applied Clinical Trials Digital Edition - February 2011, Supplementalmost 16 years ago
Rates Increase Abroad Due to High Demandalmost 16 years ago
Hispanics Remain Minority in Clinical Trialsalmost 16 years ago
State Cash Fuels Growth in Englandalmost 16 years ago
Act Coveralmost 16 years ago
Biosimilars in the US & EU Regulatory Pathwaysalmost 16 years ago
The FDA's Guidance on PROalmost 16 years ago
H1N1 Influenza: Not to be Sneezed atalmost 16 years ago
New Approach to System ValidationRelated to this article







